The US Food and Drug Administration (FDA) just green-lighted Filament Health Corporation, a clinical-stage company in the natural psychedelic medicine development business, to do a study on the effects of certain psychedelic drugs. Filament has already created around 70 strains of psychedelic mushrooms to be used for research, and they were able to raise a cool $2.5 million to continue studying the use of psychedelics through stabilized formulas. These would offer patients the benefits of better bioavailability, consistency, and a quicker onset as well as a reduction in side effects.
The years-long push to lock foreign visitors out of the city’s coffeeshops just died in…
When most people think about major hip-hop festivals, Montana rarely enters the conversation. For decades,…
From a black currant sour to an espresso martini riff, here are five THC cocktails…
In the music video for “Ram Pam Pam,” Venezuelan artist Micro TDH put older women…
The new cannabis beverage boom isn’t really about replacing booze. It’s about replacing everything people…
Amber Senter co-founded Supernova Women, the organization that helped shape America’s first cannabis social equity…